
    
      Approximately 60 subjects (15 per arm) are planned for enrollment. Subjects will be
      randomized in a 1:1:1:1 ratio to receive either DepoTXA 400 mg, DepoTXA 800 mg, DepoTXA 1200
      mg, or IV TXA (CyklokapronÂ® 1 gram).
    
  